<prompt> All are true about Erlotinib except:Used in non small cell carcinoma of lungIt is a small molecule tyrosine kinase inhibitor acting as EGFR antagonistFood decreases absorptionIt causes skin rashes and diarrhea  <response>: Erlotinib is a quinazoline derivative that selectively and reversibly inhibits the tyrosine kinase activity of the EGFR. USES: Non-Small Cell Lung Cancer Indicated for patients with metastatic non-small cell lung cancer NSCLC whose tumors have epidermal growth factor receptor EGFR exon 19 deletions or exon 21 L858R substitution mutations as detected by an FDA-approved test receiving first-line, maintenance, or second-line treatment after progression following at least 1 prior chemotherapy regimen 150 mg PO qDay 1 hr before or 2 hrs after meals Continue until disease progression or unacceptable toxicity NSCLC limitations of use Not recommended for use in combination with platinum-based chemotherapy Safety and efficacy has not been evaluated as first-line treatment in patients with metastatic NSCLC whose tumors have EGFR mutations other than exon 19 deletions or exon 21 L858R substitution Pancreatic Cancer Indicated for first-line treatment in patients with locally advanced, unresectable, or metastatic pancreatic cancer 100 mgday PO with gemcitabine Continue until disease progression or unacceptable toxicity. Malignant Gliomas Mechanism of Action: EGF receptor tyrosine kinase inhibitor; TKI inhibition possibly blocks angiogenesis and cellular proliferation Pharmacokinetics Absorption: 60 Bioavailability: 60 increased by food to almost 100 Peak Plasma Time: 4 hr Half-life: 36 hr Clearance: 24 higher in smokers Protein Bound: 93 Metabolism: primarily by CYP3A4; to a lesser extent by CYP1A2, and the extrahepatic isoform CYP1A1 Excretion: Feces 83; urine 8 REFERENCE: 